• Revenue up 127.9% to $101,409
• Loss after tax up 145.2% to $13,262,514
• Secured FDA clearance for EchoSolv AS, commenced US commercialization
• Positive results from EchoSolv HF clinical studies, pre-submission meeting with FDA

Echo IQ Limited, a medical technology company focused on improving decision making in cardiology, has reported its preliminary financial results for the year ended 30 June 2025. The company's revenue from ordinary activities increased by 127.9% to $101,409, while the loss from ordinary activities after tax grew by 145.2% to $13,262,514. These results reflect Echo IQ's continued investment in product development and commercialization efforts, particularly in the United States. Key highlights include: - Received FDA clearance for EchoSolv AS, a machine learning and AI-based decision support software for assessing aortic stenosis, and commenced commercialization through a flagship integration with Beth Israel Deaconess Medical Center in Boston. - Announced positive results from two clinical studies evaluating the company's AI-based heart failure decision support tool, EchoSolv HF, which demonstrated significantly higher accuracy compared to current clinical practice. The company also held a pre-submission meeting with the FDA to advance the regulatory pathway for EchoSolv HF. - Expanded the distribution of EchoSolv AS through partnerships and integration agreements with leading US healthcare technology providers, ScImage and MedAxiom, reaching a network of 36 hospitals and cardiology practices. - Appointed a US-based CEO, Mr. Dustin Haines, to lead the company's commercialization and growth strategy, and strengthened the board with the addition of US healthcare and medical technology executive, Mr. Ken Nelson. - Raised a total of $24.4 million through two placements to institutional and sophisticated investors, providing the company with financial flexibility to advance its US commercialization efforts, pursue FDA clearance for EchoSolv HF, and support ongoing product development and working capital requirements.

The company did not provide any high-importance, price-sensitive forward-looking financial metrics in the announcement.

The company did not provide a specific outlook statement in the announcement. However, the announcement highlights the company's continued focus on advancing its AI-driven echocardiography solutions, particularly EchoSolv AS and EchoSolv HF, through regulatory clearances, commercialization, and partnership agreements in key markets like the United States.